OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
用户h1yJrQGyoC3I
3天前
42
10
已关闭
DOI:
文献链接:
其他信息:

